Nuveen LLC Takes Position in Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• Nuveen LLC has made a significant investment in Kiniksa Pharmaceuticals, acquiring 765,054 shares worth approximately $16.99 million, which represents about 1.05% of the company's stock.
• Several institutional investors have also increased their stakes in Kiniksa, leading to hedge funds collectively owning 53.95% of the company.
• Kiniksa Pharmaceuticals reported a net revenue of $156.80 million for the last quarter, surpassing analysts’ expectations, while its stock currently has an average target price of $41.17 according to several research analysts.

Nuveen LLC purchased a new position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 765,054 shares of the company's stock, valued at approximately $16,992,000. Nuveen LLC owned 1.05% of Kiniksa Pharmaceuticals International at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Wealth Enhancement Advisory Services LLC acquired a new stake in Kiniksa Pharmaceuticals International in the first quarter worth $301,000. GAMMA Investing LLC grew its holdings in Kiniksa Pharmaceuticals International by 84.8% in the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after purchasing an additional 568 shares during the period. Deutsche Bank AG grew its holdings in Kiniksa Pharmaceuticals International by 177.1% in the first quarter. Deutsche Bank AG now owns 394,522 shares of the company's stock worth $8,762,000 after purchasing an additional 252,125 shares during the period. Victory Capital Management Inc. acquired a new stake in Kiniksa Pharmaceuticals International in the first quarter worth $1,184,000. Finally, Nuveen Asset Management LLC grew its holdings in Kiniksa Pharmaceuticals International by 7.3% in the fourth quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock worth $15,737,000 after purchasing an additional 54,361 shares during the period. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Jefferies Financial Group raised their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a report on Tuesday, July 29th. Wells Fargo & Company raised their price target on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a report on Wednesday, July 9th. Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 2nd. Finally, Wedbush reaffirmed an "outperform" rating and issued a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Six research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals International currently has an average rating of "Buy" and a consensus target price of $41.17.

Kiniksa Pharmaceuticals International Stock Performance

Shares of Kiniksa Pharmaceuticals International stock traded up $0.17 during trading hours on Friday, reaching $33.75. The company's stock had a trading volume of 356,168 shares, compared to its average volume of 705,288. Kiniksa Pharmaceuticals International, plc has a one year low of $17.82 and a one year high of $34.55. The company has a market capitalization of $2.50 billion, a P/E ratio of 843.96 and a beta of 0.14. The stock's fifty day simple moving average is $29.78 and its two-hundred day simple moving average is $25.53.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The firm had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Thomas Malley sold 78,233 shares of the stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $33.09, for a total value of $2,588,729.97. Following the completion of the sale, the director owned 12,546 shares in the company, valued at $415,147.14. This represents a 86.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider John F. Paolini sold 29,325 shares of the stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $32.55, for a total transaction of $954,528.75. Following the completion of the sale, the insider owned 57,403 shares of the company's stock, valued at approximately $1,868,467.65. This represents a 33.81% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 674,849 shares of company stock valued at $21,144,188 over the last 90 days. 53.48% of the stock is currently owned by company insiders.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.